The Medical Care Costs of Obesity: An Instrumental Variables Approach by John Cawley & Chad Meyerhoefer
NBER WORKING PAPER SERIES
THE MEDICAL CARE COSTS OF OBESITY:









The views expressed herein are those of the authors and do not necessarily reflect the views of the
National Bureau of Economic Research.
NBER working papers are circulated for discussion and comment purposes. They have not been peer-
reviewed or been subject to the review by the NBER Board of Directors that accompanies official
NBER publications.
© 2010 by John Cawley and Chad Meyerhoefer. All rights reserved. Short sections of text, not to exceed
two paragraphs, may be quoted without explicit permission provided that full credit, including © notice,
is given to the source.The Medical Care Costs of Obesity:  An Instrumental Variables Approach
John Cawley and Chad Meyerhoefer




This paper is the first to use the method of instrumental variables (IV) to estimate the impact of obesity
on medical costs in order to address the endogeneity of weight and to reduce the bias from reporting
error in weight.  Models are estimated using data from the Medical Expenditure Panel Survey for 2000-
2005.  The IV model, which exploits genetic variation in weight as a natural experiment, yields estimates
of the impact of obesity on medical costs that are considerably higher than the correlations reported
in the previous literature.  For example, obesity is associated with $676 higher annual medical care
costs, but the IV results indicate that obesity raises annual medical costs by $2,826 (in 2005 dollars).
The estimated annual cost of treating obesity in the U.S. adult non-institutionalized population is $168.4
billion or 16.5% of national spending on medical care.  These results imply that the previous literature
has underestimated the medical costs of obesity, resulting in underestimates of the cost effectiveness
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In the United States, the prevalence of obesity, defined as a body mass index
1 or BMI > 
30, has been rising for at least five decades (e.g. Burkhauser et al., 2009; Komlos and Brabec, 
2010) and has more than doubled in the past thirty years (Flegal et al., 1998).  In 2007-2008, 
33.8% of American adults were clinically obese (Flegal et al., 2010).  This is troubling because 
obesity is associated with an increased risk of myocardial infarction, stroke, type 2 diabetes, 
cancer, hypertension, osteoarthritis, asthma, and depression, among other conditions (Dixon, 
2010). 
Many previous papers have estimated the correlation of obesity with medical care costs 
(e.g. Finkelstein et al., 2009; Trasande et al., 2009; Thorpe et al., 2004; Finkelstein et al., 2003; 
Kortt et al., 1998).  Typically, this involves estimating cross-sectional models using large 
secondary datasets such as the National Medical Expenditure Survey of 1987 (NMES) and the 
more recent Medical Expenditure Panel Survey (MEPS).  The most recent such paper, which 
examines data from the MEPS, estimates that the obese had average medical spending that was 
$1,429 (in 2008 dollars), or 41.5%, higher than the average medical spending of healthy weight 
individuals, and that the aggregate medical costs associated with obesity totaled $86 billion 
(Finkelstein et al., 2009).   
These studies have made an important contribution to the literature by demonstrating the 
significance of medical costs associated with obesity and diseases linked to obesity.  As a result, 
these papers have been heavily cited and widely influential.
2  For example, these estimates have 
                                                 
1 Body mass index is defined as weight in kilograms divided by height in meters squared. 
2 For example, Finkelstein et al. (2003) has been cited 210 times, as of September 1, 2010, according to the ISI 
Web of Knowledge. 3 
 
been used to calculate the cost effectiveness of anti-obesity interventions (Brown et al., 2007; 
Wang et al., 2003) and to justify government action (e.g. U.S. D.H.H.S., 2010). 
However, the previous estimates have important limitations.  The most significant is that 
they represent the correlation of obesity with medical care costs, not the causal effect of obesity 
on medical care costs.  The correlation is an overestimate of the causal effect if, for example, 
some people became obese after suffering injury or chronic depression, and have higher medical 
costs because of the injury or depression (which is likely to be unobserved by the 
econometrician).  The correlation is an underestimate of the causal effect if, for example, obese 
people have less access to treatment (e.g. if they are more economically disadvantaged in ways 
unobserved by the econometrician).  Another limitation is that these studies are usually based 
on self-reported, rather than measured, height and weight, and this reporting error biases the 
coefficient estimates (Bound, Brown and Mathiowetz, 2002). 
This paper builds on the previous research by addressing both of these problems – 
endogeneity of weight and reporting error in weight – by estimating models of instrumental 
variables.  Our instrument for the respondent’s weight is the weight of a biological relative, an 
instrument used in the previous literature to estimate the impact of weight on other outcomes 
such as wages (e.g. Cawley 2004; Kline and Tobias, 2008) and mortality (Smith et al., 2009).  
We estimate the IV model using the 2000-2005 MEPS, the leading source of data on medical 
care costs and utilization for the U.S. non-institutionalized population.  Our results indicate that 
the effect of obesity on medical care costs is much greater than previously appreciated.  The 
model also passes two falsification tests: it does not find an impact of obesity on medical care 
costs for conditions that are unrelated to obesity, and biologically unrelated children (e.g. 
stepchildren) are not significant predictors of respondent weight. 4 
 
We allow for nonlinearities in the relationship between BMI and medical care costs, and 
show that predicted medical expenditures are U-shaped across the BMI continuum.  This 
implies that much of the medical cost of obesity is attributable to a small percentage of the 
population with very high body weight.    
The limitations of cost of illness studies are widely recognized (Shiell et al., 1987; Roux 
and Donaldson, 2004).  For example, they are not useful for prioritizing the allocation of  
medical resources because that would amount to a circular argument: some conditions have a 
large amount of resources devoted to them and thus have a high cost of illness, but that does not 
imply that even more funding is needed (see, e.g., Shiell et al., 1987).   This paper does not 
estimate the medical care costs of obesity in order to argue that treatment of obesity should be 
prioritized above treatment of other conditions, but so that the medical care consequences of 
obesity will be more accurately known, so that, e.g., the external costs of obesity through health 
insurance may be better understood and so that future studies can more accurately calculate the 
cost-effectiveness of interventions to prevent obesity.   
 
Empirical Model 
Identification: Method of Instrumental Variables 
  Ideally, to measure the effect of obesity on medical care costs we would conduct a 
randomized controlled trial in which a large number of people would be divided between a 
treatment group and a control group, after which the treatment group would be endowed with 
enough extra weight to make them obese.  By comparing the medical costs before and after the 
treatment, between the treatment and control groups (i.e. a difference in differences model) we 
could accurately estimate the causal effect of obesity on medical costs.  Such a randomized 5 
 
experiment would, of course, be unethical, so we must rely on a natural experiment.  We follow 
the previous literature (e.g. Cawley 2004; Kline and Tobias, 2008; Smith et al., 2009) and use 
the weight of a biological relative as an instrument for the weight of the respondent.   
There are two requirements for an instrument.  First, it must be powerful.  The weight of 
a biological relative is a powerful predictor of the weight of a respondent because roughly half 
the variation in weight across people is genetic in origin (Comuzzie and Allison, 1998).  As we 
describe in the Results section below, our instrument set easily exceeds the conventional 
benchmark for power of F=10 in the first stage (Stock, Wright and Yogo, 2002).  The second 
requirement is validity – the instrument must be uncorrelated with the error term in the second 
stage.  In the present context, this means that the weight of a biological relative must be 
uncorrelated with the respondent’s residual medical care costs after controlling for predicted 
respondent weight and other observed characteristics. 
One might be concerned that the second requirement is not met if the weight of both the 
respondent and the biological relative are affected by a common household environment that is 
also directly correlated with the respondent’s medical expenditures.  However, research in 
behavioral genetics finds no detectable effect of shared household environment effect on 
weight. Adoption studies have consistently found that the correlation in weight between a child 
and its biological parents is the same for children raised by their biological parents and children 
raised by adoptive parents (Vogler et al, 1995; Stunkard et al, 1986; Sorensen and Stunkard, 
1993). Other studies have found that the weights of unrelated adopted siblings are uncorrelated 
(Grilo and Pogue-Geile, 1991). Studies of twins reared apart (which by necessity are based on 
small samples) also find no effect of a shared family environment on weight; i.e. there is no 6 
 
significant difference between the correlation in the weight of twins reared together and twins 
reared apart (Price and Gottesman, 1991; Maes et al, 1997).   
With hundreds of behavioral genetics studies on the subject, there are of course some 
studies that detect a shared family environment on BMI (e.g. Nelson et al., 2006), but the 
preponderance of evidence is that any such effects are so small as to be undetectable and 
ignorable (Hewitt, 1999; Grilo and Pogue-Geile, 1991; Maes et al., 1997).  For example, a 
recent study using the same data as Nelson et al. (2006) concluded: “We also did not find any 
support for shared environmental effects on BMI at any age.” (Haberstick et al., 2010, p. 501). 
This may be contrary to conventional wisdom but it is a robust finding; a comprehensive 
review concluded that “[E]xperiences that are shared among family members appear largely 
irrelevant in determining individual differences in weight and obesity” (Grilo and Pogue-Geile, 
1991), and more recently Wardle et al. (2008) note: “Contrary to widespread assumptions about 
the influence of the family environment, living in the same home in childhood appears to confer 
little similarity in adult BMI beyond that expected from the degree of genetic resemblance.” 
(Wardle et al., 2008, p. 398.) 
As a result of this surprising but consistent finding, the similarity in weight between 
biological relatives can be attributed to genetics, which provides us with a plausible natural 
experiment to identify the causal impact of weight on medical care costs.  (To reassure 
economists concerned whether this identifying assumption would pass muster with the medical 
community, we note that the use of the weight of a biological relative as an instrument for the 
weight of a respondent in an IV model passed peer review of the British Medical Journal; see 
Smith et al. (2009)).  Later in this paper we conduct a falsification test that uses the weight of a 
stepchild (when available) instead of a biological child and find that the weight of a stepchild is 7 
 
not a significant predictor of respondent weight.  This finding is one more piece of evidence 
consistent with a lack of common household environment effect in weight. 
In the previous literature on the medical care costs of obesity, coefficients are likely 
biased because of measurement error in BMI that is due to using self-reported, rather than 
measured, weight and height.
3  (Only self-reports or proxy-reports of weight and height are 
available in the MEPS.)  Numerous studies have documented systematic misreporting of height 
and weight (e.g. Plankey et al, 1997; Villanueva, 2001).  For example, Cawley and Burkhauser 
(2006) examine data from the National Health and Nutrition Examination Survey III, which 
contains data on both self-reported and measured weight and height.  Using self-reported, rather 
than measured, data to calculate BMI results in considerable underestimation of the prevalence 
of obesity; e.g. among white females, the prevalence of obesity is 21.57% based on 
measurements but 17.42% based on self-reports (Cawley and Burkhauser, 2006).  Another 
source of reporting error is that much of the information contained in the MEPS is reported by a 
single household member, or proxy, and it is possible that proxies may not provide accurate 
height and weight information for others in the household (on the other hand, proxies may be 
more honest about other people’s weight than respondents are about their own weight).  Both of 
these sources of reporting error are expected to bias the coefficient estimates in the previous 
literature.  An additional benefit of the IV method is that it addresses the problem of 
measurement error (see, e.g. Bound et al., 2002).  
   
                                                 
3 The direction of the bias due to reporting error in weight is ambiguous, because the reporting error in weight is 
not classical – errors are not independent of the true value of the variable; in particular, those who are heavier tend 
to underreport their weight more.  See Burkhauser and Cawley (2008) for more on reporting error in weight, and 
see Bound et al. (2002) for details on the bias resulting from reporting error and the use of IV methods to reduce 
bias from reporting error. 8 
 
Two-Part Model of Medical Expenditures 
To estimate the impact of BMI and obesity on medical spending we use a two-part 
model (2PM) of medical expenditures (Jones, 2000).  The first part of the 2PM estimates the 
probability of positive medical expenditures, while the second part estimates the level of 
medical expenditures conditional on having any.  We specify the first part as a Logit model and 
the second part as a Gamma GLM with log link.
4  Following the suggestion of Manning and 
Mullahy (2001), we used modified Park tests to determine the proper choice of the conditional 
variance function for the GLM, and Hosmer-Lemeshow tests to confirm that our choice of link 
function is consistent with the data generating process.
5 
Given our specification of the 2PM, both parts of the model require the use of nonlinear 
instrumental variables techniques.  Because both the Logit model and the Gamma model are 
among the class of GLMs, one can use the instrumental variable estimator of Carrol et al. 
(1995) and Hardin et al. (2003) to determine the effect of weight on medical expenditures when 
                                                 
4 Identifying the appropriate function form for the second part of 2PM requires analysis of various characteristics of 
the expenditure distribution.  An additional consideration in this case is that we seek to provide estimates for the 
overall population of non-elderly adults as well as seven sub-populations (men, women, white, non-white, private 
insurance, Medicaid, uninsured), so our estimator must perform well across sixteen different combinations of data 
sample and empirical specification.  The two most widely used estimators for the second part of the 2PM are: 1) 
OLS of the log of the dependent variable; and 2) the GLM estimator.  A significant drawback of the log OLS 
approach is that re-transformation of the estimates back to the raw scale requires knowledge of the degree and form 
of heteroscedasticity.  In our application this would entail the difficult task of accurately diagnosing and correcting 
for heteroscedasticity on each sub-sample, making the GLM approach attractive in comparison.  However, GLMs 
can be inefficient if the log-scale disturbances are heavy-tailed (Manning and Mullahy, 2001), so we examined the 
kurtosis of the log-scale residuals from an OLS model of medical expenditures and found it has an average value of 
3.2 in our data.  While this is slightly larger than the normal distribution, a properly specified GLM model should 
be reasonably efficient under this degree of skewness. 
5 The Park tests indicated that the conditional variance is proportional to the square of the conditional mean (λ 
ranges from 1.91 - 2.06 and is precisely estimated), which is consistent with a gamma-class model.  To perform the 
Hosmer-Lemeshow tests we regressed the prediction errors from each model on deciles of the distribution of 
predicted expenditures.  If the F-test of coefficients on the decile indicators is jointly significant it indicates that the 
model does not fit the data well over the distribution of predicted expenditures.  We rejected the null hypothesis 
that the decile coefficients are jointly equal to zero for only three out of sixteen models, which suggests that the 
gamma model with log link is broadly appropriate.  In addition, Hill and Miller (2009) found that this specification 
performed relatively well on the 1996-2003 sample of non-elderly MEPS respondents with private insurance. 9 
 
the endogenous and mismeasured regressor is either BMI or a discrete indicator for obesity.
6  In 
both cases, our primary set of instruments for the two-part IV models is the BMI, BMI squared, 
and BMI cubed of the respondent’s oldest biological child.
7 
  Prior research suggests that the relationship between body weight and health status is 
nonlinear.  In particular, the underweight (BMI<18.5) and obese (BMI>=30) have higher 
mortality than the healthy weight (18.5<=BMI<25) and overweight (25<=BMI<30) (Flegal et 
al., 2005; Seidell, 1996).  To accommodate nonlinearities in the relationship between medical 
expenditures and weight status we estimate a second set of two-part IV models in which the 
endogenous regressors are the respondent’s BMI and BMI squared.  We also estimated exactly 
identified IV models that include as endogenous regressors the respondent’s BMI, BMI squared, 
and BMI cubed.  This specification confirms the U-shaped relationship, but we report results 
from the model that includes BMI squared but not BMI cubed because the confidence intervals 
around predicted medical expenditures are much narrower.  
                                                 
6 This approach incorporates  a linear first stage, which is most appropriate when the endogenous and mismeasured 
regressor is continuous.  While it is  not uncommon in applied research to employ IV methods that incorporate a 
linear first stage in cases where this regressor is discrete, the resulting coefficient estimate is not unbiased.  If the 
regressor suffers only from nonclassical measurement error then the true effect will generally lie between the OLS 
and IV estimate in the case of a simple univariate regression (Black et al. 2000 ).  When the regressor of interest is 
both endogenous and mismeasured, Frazis and Loewenstein (2003) demonstrate that the true effect lies within 
bounds applied to the IV estimate.  An alternative approach is to specify the exact distribution of both the binary 
endogenous regressor and the outcome variable.  Even if the distributional assumptions are not correct and the 
treatment effect estimate is biased, this estimator may still be preferred from a mean square error standpoint.  Deb's 
treatment effects gamma model provides an estimator of this type that is appropriate for modeling skewed 
outcomes, such as medical expenditures (Deb, 2007).  The estimation approach makes use of simulated maximum 
likelihood techniques to predict the impact of the treatment variable (obesity), which is assumed to follow a normal 
distribution, on an outcome variable (medical expenditures) generated from a gamma distribution (Deb and 
Trivedi, 2006a and 2006b).  To test the sensitivity of our results to an alternative estimator that explicitly accounts 
for the discrete nature of the endogenous and mismeasured  regressor, we re-estimated all of our models using the 
treatment effects gamma model.  While the marginal effects of obesity we derived using this approach were very 
similar to those derived from the approach of Carrol et al. (1995) on all samples except the uninsured, we prefer the 
method of Carrol et al. (1995) because it produced more consistent medical expenditure predictions across the full 
range of the BMI distribution. 
7 We obtained similar results using three other instrument sets: (1) BMI, BMI squared, and BMI cubed of the 
youngest child; (2) BMI and BMI squared of the youngest child and the BMI of the second youngest child; (3) 
BMI and BMI squared of the oldest child and the BMI of the second oldest child.  All instrument sets have the 
same theoretical justification, but we prefer the BMI, BMI squared, and BMI cubed of the oldest child because 
there is a higher response rate to the height and weight questions for older children.  10 
 
  The impact of obesity on medical expenditures may vary across the distribution of 
medical spending.  Furthermore, the marginal impact on medical expenditures of an increase in 
body weight is presumably greater for individuals of poorer health status with multiple chronic 
conditions.  To explore this possibility we estimate the conditional quantile treatment effect 
(QTE) of obesity at different points in the medical expenditure distribution using Frolich and 
Melly's (2008) implementation of the IV estimator of Abadie, Angrist, and Imbens (2002). In 
this case the instrument must be discrete, so we use the obesity status of the oldest biological 
child.
8   
   All of our IV models control for the following regressors:  gender, race/ethnicity (white, 
black, Hispanic, other race), respondent age (indicators for whether age in years is 20-34, 35-44, 
45-54, or 55-64), education level (no high school diploma, high school graduate, some college, 
bachelor’s degree or higher), census region (northeast, midwest, south, or west), whether the 
respondent lives in an MSA, household composition (number of household members age 0-5 
years, 6-17, 18-64, and 65 or older), whether the survey information was self-reported as 
opposed to proxy-reported, whether the individual was employed, fixed effects for year, the 
gender of the oldest child, and the age of the oldest child in months.
9  For sub-group estimates 
the set of regressors is modified to drop irrelevant control variables.   
   
                                                 
8 Obesity is defined as a BMI at or above the 95th percentile for children of the same age and gender according to 
the 2000 CDC growth charts (U.S. D.H.H.S., 2000). 
9 In addition to this standard set of regressors we also estimate models that include controls for health insurance 
status (private or public insurance), employer size (indicators of whether the firm contained less than 25, 25-100, 
101-500, or over 500 employees), whether the individual belonged to a union, whether the individual was married, 
and net income per adult equivalent (total household income minus health insurance premiums divided by the 
square root of household size).  Including these additional regressors has little effect on the estimated impact of 
BMI and obesity on medical expenditures.   11 
 
Data: Medical Expenditure Panel Survey (MEPS) 
The Medical Expenditure Panel Survey (MEPS) is a comprehensive, nationally 
representative survey of the U.S. civilian non-institutionalized population that has been 
conducted annually since 1996 and uses an overlapping panel design.  Respondents are 
surveyed about their medical care use and expenditures over the course of two years through 
five interview rounds.  In addition, information from the household is supplemented by 
expenditure data collected directly from participants’ medical service providers and pharmacies 
through a Medical Provider Component.  We use data from the 2000-2005 waves of the MEPS, 
and convert medical expenditures in each year to 2005 dollars.   
We limit the sample to adults between the ages of 20 and 64 with biological children 
between the ages of 11 years (132 months) and 20 years (240 months), and exclude pregnant 
women.  Relationship mappings contained in the restricted-use MEPS data allow us to identify 
biological children, stepchildren, and foster children and thus ensure that only biological 
children are used as instruments.  We do not use information on children younger than age 11 
because rates of non-response for their height and weight begin to exceed 14% and worsen as 
the children get younger.  Weight and height of each individual in the household is reported by 
a single respondent, most often the wife/mother.
10  We excluded eighteen individuals with 
implausibly high BMIs (greater than 80), as well as two individuals with extremely high 
reported medical expenditures in excess of $292,000, bringing our final estimation samples to 
9,852 men and 13,837 women.    
 We use two primary measures of medical spending in our empirical models: total 
medical expenditures and expenditures by all third party payers (typically, public and private 
                                                 
10 The exception to this is when all adult members of the household are present during the interview, in which case 
each adult will self-report their own height and weight. 12 
 
insurers).  These include all spending on inpatient events, ambulatory visits, prescription drugs, 
and home health care services, but exclude spending on over-the-counter medications.  Medical 
expenditures by source of payment are collected directly from households as well as from the 
household's medical care providers for every medical event.  In addition, MEPS respondents are 
asked whether their medical visits or other events are related to any specific medical conditions.  
These responses are then professionally coded using the International Classification of 
Diseases, Ninth Revision (ICD-9), and subsequently collapsed to into 259 clinically relevant 
medical conditions using the Clinical Classification System (CCS) developed by the Agency for 
Healthcare Research and Quality (AHRQ, 2007).   
MEPS data are collected through a stratified multi-stage probability design, which we 
account for in the calculation of the standard errors for our marginal effects.  In particular, we 
use the method of balanced repeated replications to estimate standard errors in our 2PM and the 
method of bootstrapping with 500 replications in the IV QTE models.  Both methods account 




Descriptive statistics for the main set of variables used in our empirical analysis are 
contained in Table 1 for men and Table 2 for women.  (The samples are limited to adults with 
biological children, as they are the only MEPS respondents for whom we can estimate the IV 
model.)  Among men, 79% incur some medical expenditures in the survey year, and the 
unconditional average medical expenditures in that year was $1,999 (which includes zeros for 
those with no expenditures) in 2005 dollars.  Among women, 88% incurred some medical 13 
 
expenditures, and the unconditional average medical expenditures in that year was $2,617.  
These expenditures are lower than those for the comparable population of all men and women 
(i.e. those both with and without biological children) (AHRQ, 2010).  For both men and women, 
approximately 78% of expenditures are covered by third party payers.    
In our sample, the average BMI (calculated using self-reported or proxy-reported weight 
and height) is 28.17 for men and 27.37 for women.  For both the men and women in our sample, 
the prevalence of obesity is 28%; this is significantly lower than the prevalence of obesity based 
on measured weight and height in the NHANES 2007-08, which is 32.2% among men and 
35.5% among women (Flegal et al., 2010).  This gap is likely due to reporting error, although to 
some extent it could be due to random variation in the samples.  Tables 1 and 2 indicate that 
25% of men and 83% of women self-report their weight; for the remainder, weight is proxy 
reported by the primary respondent for the household.   
Power and validity of instruments 
We now present empirical evidence regarding the power and validity of the instruments.  
Because we must test the power of our instrument set in both parts of the 2PM across seven 
populations for two measures of weight status (BMI and obesity), we calculated 32 first stage F-
statistics.  The values of the F statistics range from 31 to 281, with an average of 144.  In each 
case, the power of the instruments easily exceeds the conventional minimum standard of power 
of F=10 (Stock, Wright, and Yogo, 2002).  In addition, Hansen's test for over-identification is 
consistent with the validity of our instruments (Hansen, 1982).  In order to compute the Hansen 
J-statistic we estimate linear IV models using GMM for both the first and second parts of the 
2PM when the endogenous regressor is BMI and when it is an indicator for obesity.  Because 
we use three instruments (BMI, BMI squared, and BMI cubed of the adult's oldest biological 14 
 
child) the J-statistic follows a chi-square distribution with 2 degrees of freedom.
11  We fail to 
reject the null hypothesis that the instruments are valid in each of the 32 tests.  
Weight, obesity, and medical expenditures   
Table 3 lists regression results for the entire sample (row 1) and various subpopulations: 
e.g. men, women, white, nonwhite, those with private insurance, those with Medicaid, and the 
uninsured.  Each cell of the table lists the marginal effect (reflecting both parts of the two-part 
model) and the standard errors of the marginal effect.  The first two columns of Table 3 contain 
the results of the non-IV two-part Gamma GLM models in which the key regressor is BMI 
(column 1) or obesity (column 2).  Column 1 indicates that weighing an additional unit of BMI 
beyond the mean is associated with $51 higher annual expenditures for the pooled sample, $61 
higher annual medical expenditures for men and $48 higher annual medical expenditures for 
women.  Column 2 indicates that obesity (relative to having a BMI less than 30) is associated 
with $676 higher medical expenditures for the pooled sample, $582 higher medical 
expenditures for men and $768 higher medical expenditures for women.   
The middle two columns of Table 3 provide results from our IV 2PM.  The point 
estimates of the marginal effects on BMI and the indicator for obesity are considerably higher 
for IV than non-IV.  The standard errors are also much higher; as a result, the IV marginal 
effects on BMI and the indicator variable for obesity are not statistically significant for men or 
Medicaid recipients, despite being much larger than the non-IV estimates that are statistically 
significant.   
                                                 
11 Letting r denote the total number of included and excluded instruments in the model, and q denote the number of 
included instruments (the right-hand-side exogenous variables), optimal GMM estimator for the parameter vector 
sets equal to zero q linear combinations of the r sample orthogonality conditions.  As a result, there are r-q sample 
orthogonality conditions that are close to zero, but are not set equal to zero.  Hansen (1982) shows that the test 
statistic based on the convergence of these orthogonality conditions to zero in probability has an asymptotic chi-
square distribution with r-q degrees of freedom.    15 
 
Column 3 of Table 3 indicates that weighing an additional unit of BMI beyond the mean 
raises medical expenditures by $154 in the pooled sample, $82 for men (which is not 
statistically significant), and $178 for women.  Column 4 indicates that obesity (relative to 
being non-obese) raises medical expenditures by $2,826 for the pooled sample, $1,171 for men 
(which is not statistically significant), and $3,696 for women.  A comparison of the results of 
the IV and non-IV models indicates that the causal effect of obesity on medical expenditures is 
four times higher than its association, for both the pooled sample and for women; in other 
words, the previous literature has considerably underestimated the impact of obesity on medical 
costs. 
Results for specific subgroups indicate that the impact of obesity on medical costs is 
higher for the uninsured ($3,496) than for those with private insurance ($2,624), but the 
difference is not statistically significant (see Table 3, column 4).  Despite the fact that the 
association between obesity and medical expenditures is twice as large for whites ($827) as 
non-whites ($414), the causal effect of obesity is nearly the same for the two groups ($2,773 for 
whites versus $2,851 for non-whites).  
  The final two columns of Table 3 list results for a model of third-party medical 
expenditures, which represent a possible pathway for obesity-related externalities.  Specifically, 
some of the medical costs of obesity may be borne by other enrollees in private insurance pools 
or by taxpayers in the form of higher expenditures by the Medicaid program.  The results in the 
final column indicate that obesity is associated with substantial externalities: obesity raises 
annual third-party medical expenditures by $2,499 in the pooled sample, which is 88% of the 
effect of obesity on total medical costs.  The impact of obesity on third-party medical 
expenditures is significantly higher for women ($3,316) than men ($978, which is not 16 
 
statistically significant).  Despite the large point estimate of the impact of obesity on third-party 
medical expenditures for the Medicaid population ($3,647), it is not statistically significant, 
meaning that one cannot reject the null hypothesis that obesity does not raise medical costs in 
this large public health insurance program. 
  Table 4 contains the predicted per capita medical expenditures of the non-obese (column 
1) and obese (column 4), with the marginal effect of obesity (the difference between the medical 
expenditures of the non-obese and obese) estimated from the IV 2PM.  For most sub-
populations, the obese have medical expenditures that are on the order of two to three times 
higher than the non-obese.  Furthermore, the increase in medical expenditures resulting from 
obesity is larger than the total predicted expenditures for the non-obese; that is, in most 
subgroups obesity causes a doubling of medical expenditures (the exception is for men, for 
whom obesity raises medical expenditures by 70%).  For the pooled sample, obesity raises 
predicted medical expenditures by roughly 50%, from $1,840 to $2,826.  For women, obesity 
raises predicted medical expenditures by roughly 90%, from $1,982 to $3,696.  The largest 
relative increase in expenditure occurs among the uninsured, for whom obesity raises medical 
expenditures by 490%, from $593 to $3,476.   
  While the marginal effects reported in Tables 3 and 4 are informative, they predict the 
impact of changes in body weight at the mean (i.e. mean BMI or mean weight of all those who 
are obese), which can be misleading if the relationship between weight and medical 
expenditures is nonlinear.  We illustrate the nonlinear relationship between predicted medical 
expenditures over the range of BMI (calculated using self-reports or proxy reports of weight and 
height, and thus contain reporting error) for all adults (Figure 1), men (Figure 2), and women 
(Figure 3), allowing for nonlinearity through the inclusion of BMI squared (in addition to BMI) 17 
 
in our IV 2PM.
12  Medical expenditures are denoted by the solid line and are measured on the 
left axis, while the distribution of individuals in the population is indicated by the dotted line 
and is measured on the right axis.  Figures 1, 2, and 3 each reveal a clear U-shaped pattern in 
which medical expenditures decline as BMI moves from the underweight to normal range, then 
remain nearly constant throughout the normal and overweight range, then increase at an 
increasing rate as BMI moves into the obese range and reaches more severe levels of obesity.  
The pattern is asymmetric, with medical expenditures much higher for the extremely obese than 
for the underweight.  Moreover, the distribution of BMI shown in dotted lines indicates that a 
very small percentage of the sample is underweight, which is associated with somewhat 
elevated medical costs, but a large percentage (28%; see Tables 1 and 2) is obese, which is 
associated with much higher medical costs.  Figures 1-3 reveal that the large average effects of 
obesity shown in Table 3 ($1,171 for men and $3,696 for women) are explained by relatively 
few individuals with very high BMI that incur very high medical expenditures.  Medical 
expenditures don't increase rapidly with BMI until BMI reaches the range of 37-40, which is 
approximately two standard deviations above the mean.    
  We next investigate whether the average treatment effect of obesity varies across the 
distribution of total expenditures.  Table 5 contains IV quantile treatment effect estimates for 






percentiles.  Obesity has a small impact on expenditures for relatively healthy individuals with 
low baseline expenditures; it raises medical expenditures by just $108 for men and $180 for 
women at the 20
th percentile of expenditures.  However, obesity raises medical  
                                                 
12 We also estimated models that included BMI, BMI squared, and BMI cubed; these models also yielded a U-
shaped pattern of medical care costs over BMI, but the standard errors were considerably higher, so we prefer the 
model that includes BMI and BMI squared but omits BMI cubed. 18 
 
expenditures significantly at the upper end of the distribution.  For example, at the 90
th 
percentile of annual medical expenditures, the IV estimate of the impact of obesity on medical 
expenditures is $2,832 for men and $8,307 for women.  At each of the five percentiles we 
examine, the point estimates for women are higher than those for men, although the estimates 
for women at the 60
th and 80
th percentiles of expenditures are not statistically significant. 
Estimates of the aggregate direct medical costs of obesity for the U.S.  
The literature on the cost of obesity is motivated in part by the desire to provide 
estimates of the direct medical cost of obesity for the U.S. population and for public and private 
payers.  Our IV estimates allow us to provide estimates of the direct cost of obesity that are 
arguably more accurate than those in the previous literature.  Table 6 contains estimates of 
annual medical costs (in 2005 USD) due to obesity based on our IV 2PM model that correspond 
to the population of adults with biological children, which averaged 33.4 million people during 
2000-2005.  Our estimates indicate that the annual direct medical cost of obesity averaged $22.9 
billion over the six year period, of which $20.6 billion (90%) was borne by third party payers.  
In the most recent data, from 2005, the cost of obesity in this population was $25.5 billion, of 
which $22.6 billion (89%) was borne by third party payers. 
  Finkelstein et al. (2009) estimate, using the 2006 MEPS, that the medical cost of obesity 
for the full non-institutionalized U.S. population of adults aged 18 and older was $85.7 billion 
in 2008 USD.  We estimate that in 2005 the medical cost of obesity among the subpopulation of 
adults with biological children was $25.5 billion.  Under the assumption that the effect of 
obesity in our subpopulation generalizes to the full non-institutionalized population of adults 
aged 18 and older, we estimate that total medical costs for the full non-institutionalized 19 
 
population of adults aged 18 and older was $185.7 billion in 2008 USD, which is roughly twice 
the estimate of Finkelstein et al. (2009).
13   
  To put our estimate of the costs of obesity in context, total U.S. health expenditures in 
2005 for the non-institutionalized populations of adults sampled in the MEPS were $1.02 
trillion (in 2005 dollars).  Generalizing to the full U.S. population of non-institutionalized adults 
and all categories of medical expenditures, our estimate of $168.4 billion (in 2005 dollars) in 
medical costs attributable to obesity implies that 16.5% of U.S. national health expenditures is 
spent treating obesity-related illness. In contrast, previous estimates of the association of obesity 
with medical costs implied that obesity is responsible for 9.1% of annual medical spending 
(Finkelstein et al., 2009). 
Generalizability 
  Because of the instrument we use in our IV models, we are forced to limit our sample to 
adults with a biological child between the ages of 11 and 20 years.  As a result, our estimates of  
obesity-attributable medical expenditures may not generalize to adults without children.  To 
explore differences between the two populations, we estimated the ordinary (non-IV) two-part 
GLM version of our model for the full sample of 20-64 year old adults (i.e. unconditional on 
number of children), as well as for the sample of 20-64 year old adults with biological children 
between the ages of 11 and 20 years.  Comparing non-IV estimates for the two groups may 
yield information about the generalizability of results based on our IV sample to the general 
population.  On average, the medical care costs associated with obesity were approximately 20 
percent larger for the full sample of adults.  One possible explanation is that the obese who have 
                                                 
13 Using the MEPS sampling weights we determined that non-institutionalized population of adults 18 years of age 
and older was 222.6 million in 2005, whereas the subpopulation of adults with biological children was 33.7 
million.  Therefore, we first multiplied our subpopulation estimate by 222.6/33.7 to inflate it to the full population, 
and then multiplied by 1.10242 (obtained from the Bureau of Labor Statistics’ inflation calculator) to inflate it from 
2005 to 2008 USD.  20 
 
biological children are in relatively better health than the obese who are childless.  Although it 
is not possible to estimate IV models for the entire population of adults, the above comparison 
suggests to us that the IV results for adults with children may underestimate the effect of obesity 
on medical care costs for the general population of adults.   
Falsification Tests 
  In order to test the validity of our results we perform two falsification tests.  The logic 
behind the first test is that there are some types of medical expenditures that obesity should not 
affect.  It is challenging to find a category of medical costs that is unrelated to obesity because 
obesity has been linked by physicians to so many ailments (see, e.g., Dixon, 2010).   However, 
we are aware of no established medical relationship between obesity and epilepsy, brain 
damage, and central nervous system disorders.  Thus, our falsification test consists of using our 
IV method to examine whether obesity appears to affect expenditures on those conditions.
14  If 
our IV method indicates that obesity affects expenditures on such conditions, then that would 
suggest that the IV method lacks specificity and that the earlier results may be spurious. 
  We first estimate the non-IV two-part GLM models, and find that an additional unit of 
BMI is associated with $87 higher spending on epilepsy, brain damage, and central nervous 
system disorders.  Given that a causal link is improbable, this result is consistent with non-IV 
models suffering from omitted variables bias.  In contrast, the results of our IV model indicate 
that the causal effect of BMI on such expenditures is a statistically insignificant $5.  Likewise, 
the results of non-IV two-part GLM indicate that obesity is associated with an additional $1,232 
in spending on epilepsy, brain damage, and central nervous system disorders, but the results of 
our IV model indicate that the causal effect of obesity on such expenditures is much smaller 
                                                 
14 Expenditures on epilepsy, brain damage, and central nervous system disorders are identified as those with 
Clinical Classification System CCS codes of 83, 85, 93-95, 210, 211. 21 
 
($83) and not statistically significant.  Our interpretation of these results is that: 1) non-IV 
models suffer from bias due to omitted variables; and 2) the IV model does not fail the 
falsification test.  Not failing a falsification test is of course different from proof that the model 
is valid, but it does increase confidence that the earlier findings are not spurious but reflect a 
true causal effect of obesity on total medical care expenditures. 
  Our second falsification test is to examine whether the weight of biologically unrelated 
stepchildren appear to be powerful instruments for respondent weight.  The logic is that 
stepchildren and stepparents, lacking any biological relation, cannot be similar in weight 
because of genetics so if the weights of the two are strongly correlated it must be for reasons 
other than genetics, which suggests that the instrument may be invalid.  There are 407 non-
elderly men and women in our original sample with stepchildren between the ages of 11 and 20.  
When we conduct F-tests of the power of our instruments in this case, the test statistics range 
between 2.1 and 4.1 and we cannot reject the null hypotheses that they are uncorrelated.  In 
contrast, the average F-statistic is 144 when we test for power on the sample of adults with 
biological children and the null is strongly rejected in all cases.   
  Falsification tests are never definitive but can be helpful in demonstrating the sensitivity 
and specificity of the model.  The results of these two falsification tests are consistent with the 
identifying assumptions of IV (i.e. the validity of the instrument) and are consistent with the 
model being sensitive and specific. 




This paper provides the first estimates of the causal impact of obesity on medical costs. 
The impact of obesity on annual medical costs (in 2005 dollars) is estimated to be $2,826 for 
men and women pooled, $3,696 for women, and $1,171 for men (which is not statistically 
significant).  These averages are driven by relatively few individuals with very high BMI and 
very high medical expenditures.  
Our IV model indicates that the causal effect of obesity on medical costs is significantly 
higher than the correlation of obesity with medical costs reported in the previous literature.  We 
find that the effect of obesity on medical care costs is $3,115, which is roughly twice the 
estimate of $1,429 in Finkelstein et al. (2009); both estimates are in 2008 dollars.
15  This 
paper’s estimate of the national medical care costs of obesity-related illness is $185.7 billion, 
which is slightly more than twice the estimate of $85.7 billion by Finkelstein et al. (2009)
16; 
both estimates are in 2008 dollars.  The results of this paper suggest that 16.5% of U.S. national 
health expenditures are spent treating obesity-related illness, which is considerably higher than 
the previous estimate of 9.1% (Finkelstein et al., 2009). 
Two important differences should be kept in mind when comparing our paper to the 
earlier literature (e.g. Finkelstein et al., 2009).  First, this paper compares the obese to the non-
                                                 
15 Specifically, the IV estimate of the impact of obesity on medical costs for men and women combined is $2,826 
in 2005 dollars (Table 3); adjusting from 2005 dollars to 2008 dollars requires multiplying by 1.10242 (according 
to the Bureau of Labor Statistics’ inflation calculator), which results in the final estimate of $3,115 in 2008 dollars. 
16 Finkelstein et al. (2009) also provide estimates of the medical care costs of obesity that are based on data from 
the 2006 National Health Expenditure Accounts which, unlike MEPS, includes the institutionalized population and 
a wider array of health-related expenditures such as over-the-counter medicines.  They multiply the fraction of total 
spending attributable to obesity from the MEPS by the total spending in NHEA, on the assumption that the 
percentage of medical costs due to obesity is the same for institutionalized and non-institutionalized populations.  
Because the NHEA covers a wider array of expenditures and the sicker institutionalized population, this results in a 
higher estimate of the aggregate medical costs of obesity: $147 billion in 2008 dollars.  We focus in this paper on 
the MEPS data and thus compare our results to the MEPS results of Finkelstein et al. (2009). 23 
 
obese (which includes the healthy weight and the overweight), whereas Finkelstein et al. (2009) 
compares the obese to the healthy-weight.  (The models used in this paper do not include an 
indicator variable for overweight because we lack additional instruments for additional 
categories of weight classification.)  It is reasonable to combine the healthy weight and 
overweight in this context, as the health care costs of the two groups are similar (see Figures 1-
3) and the overweight do not have higher mortality risk than the healthy-weight (see e.g. Mehta 
and Chang, 2009, and Flegal et al., 2005).  A second important difference to keep in mind is 
that the estimates in this paper are based on adults with at least one biological child (because of 
our IV strategy), whereas the previous literature typically uses all adults.  As a result, the 
individuals in our sample may be healthier on average. 
One might ask whether our estimates of the causal effect of obesity on medical costs are 
implausibly high.  Physicians have documented biological pathways through which obesity 
raises the risk and severity of type 2 diabetes, sleep apnea, hypertension, myocardial infarction, 
stroke, gallstones, gout, cancer, osteoarthritis, asthma, and gastroesophageal reflux (see, e.g., 
Dixon, 2010).  Part of the challenge in identifying an appropriate falsification test was finding 
conditions for which there was no medical literature linking it to obesity.  Estimates of the 
impact of obesity on medical care costs would be suspect if they were not substantial.  There are 
at least two reasons that our estimates are higher than the associations reported in the previous 
literature.  First, previous estimates likely suffer omitted variables bias; e.g., obese people may 
also be disadvantaged and lack access to medical care.  Second, reporting error in weight and 
height may bias previous estimates, and this reporting error is addressed by our IV method. 
Our finding that the causal impact of obesity on medical care costs is greater than 
previously appreciated has important implications.  For example, many estimates of the cost-24 
 
effectiveness of anti-obesity interventions are based on published estimates of the association of 
weight with medical care costs, which underestimate the causal effect.  For example, cost-
effectiveness estimates for the school-based interventions Coordinated Approach to Child 
Health or CATCH (Brown et al., 2007) and Planet Health (Wang et al., 2003) are based on the 
estimates of the association of weight with medical costs reported in Gorsky et al. (1996) and 
Oster et al. (1999).  As a result, the cost-effectiveness of CATCH and Planet Health have likely 
been underestimated. 
Likewise, the results of this paper are informative regarding the cost effectiveness of 
government programs to reduce and prevent obesity.  Trasande (2010) recently estimated the 
cost-effectiveness of government spending to reduce childhood obesity using the estimates of 
adult medical expenditures attributable to obesity from Finkelstein et al. (2009).  To the extent 
that our IV estimates are more accurate estimates of the impact of obesity on medical care costs, 
Trasande (2010) understates the cost-effectiveness of government spending to reduce childhood 
obesity. 
The results of this paper also indicate that insurance companies spend more treating 
obesity-related illness than was previously thought, and thus there may be a better business case 
for insurance companies to cover effective treatments for obesity (such as prescription drugs for 
weight loss (e.g. Xenical and Meridia), bariatric surgery, and nutrition counseling) than was 
previously appreciated.   
The externalities associated with obesity that operate through insurance are also greater 
than previously appreciated.  Our estimates indicate that obesity raises third-party spending on 
medical care by $2,499 (this includes spending by private insurers as well as public insurers 25 
 
such as Medicaid).  One approach to limiting such externalities in private health insurance is to 
vary insurance premia based on weight, although this also limits the extent of risk-pooling. 
The magnitude of externalities is also relevant for government policy because “External 
costs provide one of the strongest economic justifications for government interventions…” 
(Zohrabian and Philipson, 2010, p. 2468).  The estimates in this paper imply that the economic 
case for government intervention to reduce obesity-related externalities has been 
underestimated.  Some have noted that one way to internalize some of the external costs of 
obesity is to charge the obese higher premiums for public health insurance such as Medicare 
(Finkelstein and Zuckerman, 2008), although that may not be consistent with the redistributive 
goals of the programs.   
Bhattacharya and Sood (2007, 2010) point out that the obesity externalities that operate 
through pooling of risk in insurance result in deadweight loss only to the extent that they distort 
decisionmaking.  (The pooling of obesity-related medical costs always results in a transfer from 
the non-obese to the obese, but this may or may not entail deadweight loss to society.
17)  There 
are two major ways that the obesity externality that operates through insurance distorts 
consumer decisionmaking.  First, consumers may buy less insurance because the pooling of 
obesity-related medical care costs raises insurance premia.  The literature on the premium 
elasticity of demand for health insurance finds that consumers are modestly sensitive to the 
price of insurance (e.g. Gruber and Washington, 2005; Marquis and Long, 1995), which is 
consistent with some deadweight loss through this channel.  The second way in which the 
obesity externality distorts consumer decisionmaking is through moral hazard; risk pooling 
ensures that the obese do not pay the full medical care costs of their obesity so they may invest 
                                                 
17 Because obesity is partly genetic, some may consider a certain amount of risk pooling through health insurance 
to be desirable.  26 
 
less in weight loss or preventing weight gain.  Using methods of instrumental variables that 
exploit state Medicaid expansions, Rashad and Markowitz (2010) and Bhattacharya et al. (2009) 
find evidence that having health insurance (i.e. the extensive margin) raises BMI.  Bhattacharya 
et al. (2009) find weaker evidence that the generosity of insurance (i.e. the intensive margin) 
raises BMI.  Bhattacharya and Sood (2007) calculate that the welfare loss in the U.S. associated 
with this second channel totals $150 per capita (in 1998 dollars).  In summary, the obesity 
related externality that operates through insurance seems to be not just a transfer from the non-
obese to the obese, but to also impose deadweight loss on society by distorting decisions about 
purchases of insurance and about optimal investment in weight loss and prevention of weight 
gain. 
Future directions for research include finding additional natural experiments that affect 
weight but do not directly affect medical care expenditures.  These would shed light on the 
generalizability of the results generated from the natural experiment we exploit.  It would also 
be useful to test explanations for differences between subsamples in the impact of obesity on 
medical expenditures.  For example, our point estimate of the impact of obesity on medical 
expenditures is higher for Medicaid recipients ($3,778) and the uninsured ($3,496) than those 
with private insurance coverage ($2,624); it would be useful to know whether this is due to 
differences in the health impact of obesity across the three groups or due to differences in access 
to medical care. 
This paper has several limitations.  The first limitation that should be discussed in any 
paper that uses IV concerns the validity of the instrument.  Our identifying assumption is that 
the weight of a biological relative is strongly correlated with the respondent’s weight, but 
uncorrelated with residual medical care costs.  A large literature in behavioral genetics confirms 27 
 
that there is a strong genetic component to weight, and that any similarity in weight due to 
shared environment is so small as to be undetectable.  However, other threats to the validity of 
the instrument are that the genes that affect weight may also affect other things that could 
directly affect residual medical care costs (pleitropy), and the genes that affect weight may lie 
next to genes that directly affect residual medical care costs (proximity matters because genes 
are inherited in blocks).  We are unable to test whether these are problems in the current 
context, and can only follow the previous literature (e.g. Smith et al., 2009; Kline and Tobias 
2008; Cawley, 2004) in acknowledging them as possible limitations of the instrument.  
Although our instrument passes the standard statistical tests for power and over-identification, 
there is no way to prove the validity of any instrument; one can only fail to reject the null 
hypothesis that the instrument is valid. 
Like the previous literature, this paper uses BMI, which has been criticized as a measure 
of fatness because it does not distinguish fat from muscle (Burkhauser and Cawley, 2008).  
Ideally, we use more accurate measures of fatness such as percent body fat, but only the 
components of BMI (weight and height) are available in the MEPS.  Another limitation is that 
weight and height are self-reported or proxy-reported instead of measured.  Although the IV 
method helps eliminate the influence of reporting error, measured values would be preferable.  
Another limitation is that we can implement our IV method only for adults with biological 
children, and thus caution should be used when generalizing our results to the entire population 
of U.S. adults.   
Despite these limitations, this paper makes an important contribution by providing the 
first estimates of the causal impact of obesity on medical care costs, which are significantly 
higher than the estimates of the association that are published in the previous literature, and thus 28 
 
have important implications for insurance, government policy, and estimates of the cost-
effectiveness of anti-obesity interventions. 
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Table 1: Descriptive statistics for sample of men with biological children (N = 9,852) 
Notes: Data: MEPS 2000-2005.  All means are weighted and monetary values expressed in 2005 USD.   
  Mean  S.D.  Min  Max 
Medical expenditures > 0  0.79  0.41  0  1 
Total medical expenditures  1,999  5,406  0  212,681 
Third party med. expenditures > 0  0.72  0.45  0  1 
Third party medical expenditures  1,577  4,970  0  197,501 
Body mass index  28.17  4.88  14.98  59.30 
Body mass index squared  817  308  224  3,516 
Obesity (BMI  ≥ 30)  0.28  0.45  0  1 
White  0.72  0.45  0  1 
Hispanic  0.14  0.35  0  1 
Black  0.09  0.28  0  1 
Other race  0.05  0.23  0  1 
Age is 20 - 34  0.06  0.24  0  1 
Age is 35 - 44  0.43  0.49  0  1 
Age is 45 - 54  0.43  0.49  0  1 
Age is 55 - 64  0.09  0.28  0  1 
No high school diploma  0.16  0.37  0  1 
High school graduate  0.34  0.47  0  1 
Some college  0.21  0.41  0  1 
Bachelor's degree or higher  0.29  0.45  0  1 
Northeastern census region  0.19  0.39  0  1 
Midwestern census region  0.24  0.43  0  1 
Southern census region  0.34  0.47  0  1 
Western census region  0.23  0.42  0  1 
Residence in MSA  0.81  0.40  0  1 
No. HH members 0 - 5  0.18  0.48  0  5 
No. HH members 6 - 17  1.74  1.02  0  9 
No. HH members 18 - 64  2.30  0.73  1  9 
No. HH members 65+  0.02  0.17  0  3 
Survey info. is self-reported  0.25  0.43  0  1 
Not employed  0.09  0.28  0  1 
Oldest child is female  0.47  0.50  0  1 
Oldest child age in months  191.44  31.20  132.00  240.00 
Oldest child BMI  22.49  5.10  7.60  109.19 
Oldest child BMI squared  532  330  58  11,923 
Oldest child BMI cubed  13,504  26,148  439  1,301,949 
Oldest child is obese  0.12  0.33  0  1 
Year is 2000  0.16  0.36  0  1 
Year is 2001  0.17  0.37  0  1 
Year is 2002  0.17  0.38  0  1 
Year is 2003  0.17  0.37  0  1 
Year is 2004  0.16  0.37  0  1 
Year is 2005  0.17  0.37  0  1 34 
 
Table 2: Descriptive statistics for sample of women with biological children (N = 13,837)   
Notes:  Data: MEPS 2000-2005.  All means are weighted and monetary values expressed in 2005 
USD.    
  Mean  S.D.  Min  Max 
Medical expenditures > 0  0.88  0.32  0  1 
Total medical expenditures  2,617  6,565  0  220,924 
Third party med. expenditures > 0  0.80  0.40  0  1 
Third party medical expenditures  2,050  6,199  0  218,323 
Body mass index  27.37  6.42  14.50  78.3 
Body mass index squared  790  410  210  6,131 
Obesity (BMI  ≥ 30)  0.28  0.45  0  1 
White  0.66  0.47  0  1 
Hispanic  0.15  0.35  0  1 
Black  0.14  0.34  0  1 
Other race  0.06  0.23  0  1 
Age is 20 - 34  0.11  0.31  0  1 
Age is 35 - 44  0.52  0.50  0  1 
Age is 45 - 54  0.34  0.47  0  1 
Age is 55 - 64  0.03  0.18  0  1 
No high school diploma  0.16  0.37  0  1 
High school graduate  0.34  0.47  0  1 
Some college  0.25  0.43  0  1 
Bachelor's degree or higher  0.24  0.43  0  1 
Northeastern census region  0.19  0.39  0  1 
Midwestern census region  0.24  0.43  0  1 
Southern census region  0.35  0.48  0  1 
Western census region  0.22  0.42  0  1 
Residence in MSA  0.81  0.39  0  1 
No. HH members 0 - 5  0.16  0.44  0  5 
No. HH members 6 - 17  1.72  1.00  0  9 
No. HH members 18 - 64  2.12  0.80  1  9 
No. HH members 65+  0.03  0.20  0  3 
Survey info. is self-reported  0.83  0.37  0  1 
Employed  0.25  0.43  0  1 
Oldest child is female  0.49  0.50  0  1 
Oldest child age in months  191.38  31.09  132.00  240.00 
Oldest child BMI  22.66  5.22  6.70  109.19 
Oldest child BMI squared  541  321  45  11,923 
Oldest child BMI cubed  13,820  23,206  2,803  1,301,949 
Oldest child is obese  0.13  0.34  0  1 
Year is 2000  0.15  0.36  0  1 
Year is 2001  0.16  0.37  0  1 
Year is 2002  0.18  0.38  0  1 
Year is 2003  0.17  0.38  0  1 
Year is 2004  0.17  0.38  0  1 
Year is 2005  0.17  0.37  0  1 35 
 
Table 3: Marginal effects of BMI and obesity on annual medical expenditures (Standard       
     errors in parenthesis) 
 
Population 
Non-IV (Total Exp.)  IV (Total Exp.)  IV (Third Party Exp.) 
BMI  Obesity  BMI  Obesity  BMI  Obesity 
Total 

























































































































(1,611)  ---  --- 
Notes:  Data: MEPS 2000-2005.  Standard errors are adjusted for the complex design of the 
MEPS and values are reported in 2005 USD.  ns denotes that the estimate is not statistically 











Table 4: Medical expenditures on obesity as a percentage of expenditures by the non-obese 

































































































Notes:  Data: MEPS 2000-2005.  Standard errors are adjusted for the complex design of the 
MEPS and values are reported in 2005 USD.  ns denotes that the estimate is not statistically 
significant at α = .10.  Marginal effect of obesity is estimated using the IV 2PM, and is reported 
in the fifth column of Table 3. 
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Table 5: Marginal (treatment) effect of obesity at different points in the distribution of total 
annual medical expenditures (Standard errors in parenthesis) 
 

































Notes:  Data: MEPS 2000-2005.  Standard errors are adjusted for the complex design of the 
MEPS and values are reported in 2005 USD.  ns denotes that the estimate is not statistically 
significant at α = .10.   38 
 
Table 6:  Annual medical cost of obesity for non-elderly adults with biological children  
(Billions of 2005 USD; 90% confidence interval in parenthesis) 
 















































(10.9, 30.2)  33.4 
Notes:  Data: MEPS 2000-2005.  Confidence intervals are adjusted for the complex design of the 
MEPS. 
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Figure 1:  Predicted relationship between BMI and annual medical expenditures for all adults with biological children  
 
   
Notes:  Data: MEPS 2000-2005.  Expenditures are in 2005 USD.  Dashed lines represent the 90% confidence interval, which has been adjusted for 
the complex design of the MEPS.  Medical expenditures are denoted by the solid line and are measured on the left axis, while the distribution of 
individuals in the population is indicated by the dotted line and is measured on the right axis.  BMI is calculated using self-reports or proxy reports 































































Obese  Overweight  Underweight  Normal weight 40 
 
Figure 2:  Predicted relationship between BMI and annual medical expenditures for men with biological children 
 
   
Notes:  Data: MEPS 2000-2005.  Expenditures are in 2005 USD.  Dashed lines represent the 90% confidence interval, which has been adjusted for 
the complex design of the MEPS. Medical expenditures are denoted by the solid line and are measured on the left axis, while the distribution of 
individuals in the population is indicated by the dotted line and is measured on the right axis.  BMI is calculated using self-reports or proxy reports 
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Figure 3: Predicted relationship between BMI and annual medical expenditures for women with biological children 
 
       
Notes:  Data: MEPS 2000-2005.  Expenditures are in 2005 USD.  Dashed lines represent the 90% confidence interval, which has been adjusted for 
the complex design of the MEPS. Medical expenditures are denoted by the solid line and are measured on the left axis, while the distribution of 
individuals in the population is indicated by the dotted line and is measured on the right axis.  BMI is calculated using self-reports or proxy reports 
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